GGrantIndex
Sort

30,917 grants matching tumor microenvironment

Novel Markers for Disease Outcome in Breast Cancer

$673,686
Stefan Ambs · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA

An organotypic model recapitulating colon cancer microenvironment and metastasis

$673,627
Emina Hui-Na Huang · Cleveland Clinic Lerner Com-Cwru · U01 · FY2018 · CA

Project 1: Multi-scale modeling of adaptive drug resistance in BRAF-mutant melanoma

$673,611
Peter Karl Sorger · Harvard Medical School · U54 · FY2020 · CA

CD200R blockade for cancer immunotherapy

$673,569
Sujit Basu · Ohio State University · R01 · FY2025 · CA

Label-Free Optical Redox Imaging for Pretreatment Prognosis of Early-Stage Triple Negative Breast Cancer

$673,463
Lin Z Li · University Of Pennsylvania · R01 · FY2025 · CA

Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122

$673,408
Antonio M Omuro · Yale University · R01 · FY2023 · CA

Addressing Chemoresistance in Pancreatic and Ovarian Cancers: Photodynamic Priming and Repurposing of Tetracyclines using Targeted Photo-Activable Multi-Inhibitor Liposome

$673,220
Huang Chiao Huang · Univ Of Maryland, College Park · R01 · FY2021 · CA

Studying phenotypic states of antitumor human T cells

$673,212
Sri Krishna · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

Early detection and risk of head and neck cancer through immune based spatial omics

$673,156
Sara Isabel Pai · Yale University · U01 · FY2024 · DE

Multicolor PET to interrogate cancer biology

$673,118
Jan Grimm · Sloan-Kettering Inst Can Research · R01 · FY2025 · EB

Harnessing the nervous system to overcome resistance to immunotherapy in oral cancer

$673,034
Moran Amit · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · DE

Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer

$672,991
Daniel J. Powell · University Of Pennsylvania · R01 · FY2022 · CA

Investigating the therapeutic potential of a novel glutamine antagonist in KEAP1 mutant lung cancer

$672,853
Thales Papagiannakopoulos · New York University School Of Medicine · R01 · FY2024 · CA

Targeting MIC to Augment Adoptive NK Therapy Using the Canine Soft Tissue Sarcoma Model

$672,844
Seth M Pollack · Northwestern University At Chicago · R01 · FY2025 · CA

A physical sciences approach to investigate the role of exosomes in metastatic progression

$672,673
Ravi Radhakrishnan · University Of Pennsylvania · U01 · FY2025 · CA

Fibronectin Modulation of Oral Cancer Nociception

$672,660
Aditi Bhattacharya · New York University · R56 · FY2025 · DE

Understanding the cellular and functional changes in the immune tumor microenvironment of glioblastoma during progression and treatments.

$672,634
Alain Charest · Beth Israel Deaconess Medical Center · R01 · FY2023 · CA

Genetically engineered mouse model to improve therapy of NUT carcinoma

$672,468
Christopher A French · Brigham And Women'S Hospital · R01 · FY2023 · CA

Ultra-sensitive mass spectrometry-based immunopeptidomics using digital microfluidics.

$672,371
Etienne Caron · Yale University · R61 · FY2025 · CA

Mechanisms of Hyperprogression to Immunotherapy in SMARCB1-Deficient Renal Malignancies

$672,300
Pavlos Msaouel · University Of Tx Md Anderson Can Ctr · R37 · FY2025 · CA

Mechanisms of Hyperprogression to Immunotherapy in SMARCB1-Deficient Renal Malignancies

$672,300
Pavlos Msaouel · University Of Tx Md Anderson Can Ctr · R37 · FY2024 · CA

Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor

$672,297
David John Tweardy · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA

Advancing immunotherapy through cross species studies of immune cell responses and immune checkpoint inhibitor effects in dogs and humans with invasive urinary bladder cancer

$672,254
Deborah W Knapp · Purdue University · U01 · FY2025 · CA

The linkage between Race, Kaiso and the tumor microenvironment in breast cancer health disparities

$672,210
Kevin L. Gardner · Columbia University Health Sciences · R01 · FY2020 · CA

PD-1/PD-L1 modulation in cancer therapy

$672,206
Drew M. Pardoll · Johns Hopkins University · R01 · FY2020 · CA